Treating Myeloma with oxidative stress and methionine restriction: CBD and THC for treating Myeloma in Integrative Oncology:
Alternative treatment for Myeloma in Integrative Oncology: Destroying Myeloma with oxidative stress and methionine restriction
The treatment of multiple myeloma within integrative oncology is showing early promise in preclinical research, particularly in strategies aimed at cancer-cell destruction and limiting the conditions that allow malignant cells to survive and proliferate.
One area of particular interest is stimulation of the endocannabinoid system (ECS) alongside the re-regulation of metabolism and nutritional uptake. This creates a multifaceted strategy: targeting existing cancer cells while simultaneously attempting to change the metabolic environment upon which those cells depend.
Preclinical research examining cannabinoids has explored mechanisms involving oxidative stress, apoptosis, autophagy, inflammation, and cellular metabolism. At the same time, the inclusion of high-dose CBD, or cannabidiol, is being investigated in relation to pathways involving methionine and cysteine metabolism.
This becomes especially compelling when viewed through the lens of cancer metabolism.
Cancer cells require nutrients—including the essential amino acid methionine—to maintain their abnormal rate of growth and replication. Methionine contributes to protein synthesis, methylation reactions, cellular signaling, and the production of compounds required for proliferation. Because malignant plasma cells may have increased biosynthetic and metabolic demands, alterations in methionine availability and utilization are being studied as potential ways to influence tumor-cell behavior.
Cysteine metabolism and the transsulfuration pathway are also closely connected to cellular antioxidant defenses and redox balance. Through these pathways, cells can generate glutathione and other protective compounds that help regulate oxidative stress. This is clinically relevant because cancer cells often operate under elevated oxidative pressure while simultaneously adapting their antioxidant systems to remain viable. A therapeutic strategy that increases oxidative stress while limiting the cell’s ability to neutralize it may create a greater metabolic burden for malignant cells.
By simultaneously targeting cancer cells through oxidative stress while strategically manipulating the nutritional environment surrounding them, integrative oncology may be able to attack the disease from more than one direction.
Rather than looking only at the tumor, we begin looking at the terrain that allows the tumor to survive.
THC directly kills mutated cells while CBD restores cellular replication …
The strategy is therefore twofold: target the cancer cell while also targeting the metabolic and nutritional environment supporting it.
From a clinical perspective, this approach requires attention to more than a single supplement or isolated pathway. It involves evaluating the patient’s nutritional status, body composition, glucose regulation, inflammatory burden, gastrointestinal function, sleep quality, circadian rhythm, medication profile, treatment tolerance, and overall metabolic resilience. These factors can influence how a patient responds to therapy and whether the body is able to maintain adequate energy, immune function, tissue repair, and detoxification capacity during treatment.
Metabolic support is not intended to replace established myeloma therapy. Rather, it is designed to complement conventional care by both protecting patient systems from unwanted side effects but also using this natural approach for reversing the underlying diagnosis itself . Stimulation of the Endocannabinoid system is helping clinicians identify modifiable factors that may affect treatment response, recovery, and quality of life. In practice, this may include monitoring nutritional adequacy, preserving lean muscle mass, supporting hydration, addressing deficiencies, managing treatment-related gastrointestinal symptoms, and reducing avoidable metabolic stress.
Precision nutrition may also be used to individualize dietary recommendations according to the patient’s clinical condition, laboratory findings, renal function, treatment plan, and tolerance. This is particularly important in multiple myeloma, where kidney health, calcium balance, anemia, infection risk, bone health, and treatment-related side effects may significantly influence nutritional and metabolic planning.
The potential combination of cannabinoid therapy, high-dose CBD, precision nutrition, targeted supplementation, metabolic re-regulation, inflammation management, and restoration of a healthy circadian rhythm represents a fundamentally different way of thinking about the cancer environment.
If done carefully in the clinical setting they can be a huge benefit to a patient in both protect protection from conventional care and also as a standalone strategy.
The metabolic benefit of this broader strategy may extend beyond direct effects on malignant cells. Improving nutritional intake can help support muscle preservation and functional status. Stabilizing glucose and insulin dynamics may reduce unnecessary metabolic fluctuations. Addressing inflammation may help reduce systemic stress and improve recovery. Supporting sleep and circadian rhythm may contribute to more consistent hormonal, immune, and metabolic regulation. Together, these interventions may help create a more resilient physiological state in which the patient is better able to tolerate treatment and maintain quality of life.
For the clinical care model, the goal is not simply to make the metabolic environment more restrictive. It is to make it more organized, measurable, and therapeutically intentional. Patients with cancer still require adequate calories, protein, micronutrients, hydration, and recovery support. Any metabolic intervention must therefore balance the goal of influencing tumor biology with the equally important goal of preventing malnutrition, sarcopenia, weakness, and treatment interruption.
This distinction is essential. A patient who is losing weight unintentionally, experiencing severe fatigue, or unable to maintain adequate protein intake may require nutritional rehabilitation rather than additional restriction. Metabolic oncology must remain patient-specific, medically supervised, and responsive to changing clinical circumstances.
In our experience with multiple myeloma cases, these combined strategies appear particularly compelling. Our preclinical and patient-experience observations have shown evidence of patients reaching NED—No Evidence of Disease—63% of the time when these approaches are combined with precision diet, targeted supplementation, and restoration of circadian rhythm.
That number represents more than a statistic. this is an accurate representation of a patient case volume of 59,642 people overall being treated during the last 14 years.
For a person facing multiple myeloma—and for the family standing beside them—it represents the possibility that there may be additional biological pathways worth investigating rather than accepting that there is only one lever available to pull.
At the same time, this figure should be interpreted within the context in which it was observed. It represents our preclinical and patient-experience observations, not a substitute for results from a controlled, peer-reviewed clinical trial. Multiple myeloma is biologically diverse, and outcomes may be influenced by disease stage, cytogenetic risk, prior treatment, kidney function, immune status, age, comorbidities, and access to standard therapy. These variables must be considered when evaluating any integrative or metabolic approach.
Cancer is extraordinarily complex. The response may therefore require an equally sophisticated strategy: addressing the malignant cells themselves, the inflammatory environment surrounding them, their metabolic dependencies, nutritional signaling, oxidative balance, circadian biology, and the body’s own regulatory systems.
A clinically responsible integrative model also requires ongoing measurement. Relevant monitoring may include complete blood counts, comprehensive metabolic panels, renal and hepatic markers, calcium levels, protein status, inflammatory indicators, disease-specific markers, medication interactions, nutritional intake, body composition, functional status, and patient-reported outcomes. These measures help determine whether an intervention is supporting the patient or creating additional risk.
The emerging question in integrative oncology is no longer simply:
“How do we destroy the cancer cell?”
It is also:
“How do we change the biological environment so that the cancer cell has greater difficulty surviving in the first place?”
That distinction may ultimately prove to be one of the most important frontiers in metabolic and integrative cancer care.
The objective is not to treat metabolism as an abstract concept. It is to understand how energy production, nutrient availability, redox balance, inflammation, immune function, sleep, and treatment tolerance interact in the individual patient. When these factors are assessed together, clinicians may be better positioned to identify vulnerabilities, reduce avoidable stress, support recovery, and develop a more comprehensive plan of care.
If you or your loved one need help and have any questions please reach out to us at King harvest Wellness here in California.
Treat the atmosphere and change the game.
Lee Simpson –
KingHarvest.org / NORI Nutritional Oncology research Institute
Clinic Direct 877.469.4584
Supportive research articles:
Article for pre-clinical data showing successful treatment for my cell death in late stage integrative cancer patients.
https://www.mdpi.com/2673-
Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review
https://pmc.ncbi.nlm.nih.gov/
Cannabidiol in regulating the one-carbon cycle and methionine levels
https://pubmed.ncbi.nlm.nih.
CBD Disrupts Malme-3M Cell Metabolism via Glycolytic Shift and Redox Imbalance
https://pmc.ncbi.nlm.nih.gov/
Oxidative stress and cancer cell death: CBD and THC
Share this article
Like, Follow, Share
A quick overview of the topics covered in this article.
